SPRCNasdaqPharmaceutical PreparationsFiscal year ends December 31

SciSparc Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$1.40−0.30 (-17.65%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 0.0
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

SciSparc has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements SciSparc filed with the SEC

Oct 15, 2026, 11:47 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES TRANSFORMATION INTO AGENTIC AI-POWERED TECHNOLOGIES, INCLUDING CYBERSECURITY AND FINANCE TECHNOLOGIES."
EX-99.1 to Form 6-K
Oct 7, 2026, 9:00 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS' CLINIQUANTUM REPORTSSUCCESSFUL QUANTUM-ENABLED ANALYSIS OF BILLIONS OF GENE COMBINATIONS USING REAL-WORLD CLINICAL DATA ON AN S&P 500 COMPANY'S QUANTUM ARCHITECTURE"
EX-99.1 to Form 6-K
Sep 30, 2026, 5:05 PM ET
AS OF JUNE 30, 2026
EX-99.1 to Form 6-K
Sep 30, 2026, 5:05 PM ET
SCISPARC LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2026
EX-99.2 to Form 6-K
Sep 24, 2026, 6:26 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA HIGHLIGHTS ENHANCEMENT OF U.S. PATENT PORTFOLIO THROUGH COLLABORATION WITH CLEARMIND COVERING LSD, KETAMINE AND IBOGAINE COMBINATIONS."
EX-99.1 to Form 6-K
Sep 2, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS ACHIEVES SIGNIFICANT ENROLLMENT MOMENTUM IN SCI-210 AUTISM CLINICAL TRIAL
EX-99.1 to Form 6-K
Sep 2, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS PURSUES FDA ORPHAN DRUG DESIGNATION FOR ADULT TOURETTE SYNDROME DRUG; ENGAGES GOVERNMENT AND PUBLIC AFFAIRS FIRM RK STRATEGIES
EX-99.2 to Form 6-K
Aug 26, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ADVANCES AGENTIC AI STRATEGY WITH ADDITION OF INTERNATIONALLY RECOGNIZED AI EXPERT PROF. CARMEL DOMSHLAK TO SCIENTIFIC ADVISORY BOARD."
EX-99.1 to Form 6-K
Aug 24, 2026, 9:21 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA-CLEARMIND COLLABORATION ADVANCES MDMA-N-ACYLETHANOLAMINES IP FOR THE TREATMENT OF PTSD AMID RISING U.S. FEDERAL SUPPORT FOR PSYCHEDELIC INNOVATION."
EX-99.1 to Form 6-K
Aug 18, 2026, 4:02 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS COMPLETES C$5.4 MILLION FINANCING WITH SCISPARC'S STAKE VALUED AT APPROXIMATELY C$30 MILLION."
EX-99.1 to Form 6-K
Aug 12, 2026, 8:58 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC'S SUBSIDIARY NEUROTHERA LABS GRANTED JAPANESE PATENT FOR ITS PROPRIETARY, INNOVATIVE THERAPEUTIC COMBINATION."
EX-99.1 to Form 6-K
Aug 5, 2026, 9:00 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS LAUNCHES PHASE IIB CLINICAL TRIAL AT YALE CHILD STUDY CENTER FOR FIRST-OF-ITS-KIND TREATMENT FOR TOURETTE SYNDROME."
EX-99.1 to Form 6-K
Jul 31, 2026, 9:15 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS' QUANTUM PLATFORM DEMONSTRATES COMPLETE END-TO-END HYBRID QUANTUM-CLASSICAL WORKFLOW FOR CLINICAL DATA ANALYTICS."
EX-99.1 to Form 6-K
Jul 29, 2026, 9:11 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES DECISION TO TARGET THE AGENTIC AI MARKET; FORMS SCIENTIFIC ADVISORY BOARD FOR ARTIFICIAL INTELLIGENCE AND CYBERSECURITY."
EX-99.1 to Form 6-K
Jul 29, 2026, 9:11 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS ADVANCES ITS QUANTUM PLATFORM FOR CLINICAL DATA ANALYTICS ON A PLATFORM OF AN S&P 500 COMPANY."
EX-99.2 to Form 6-K
Jul 15, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS ANNOUNCES INITIATION OF PHASE IIB CLINICAL TRIAL AT HANNOVER MEDICAL SCHOOL IN GERMANY FOR INNOVATIVE TREATMENT OF TOURETTE SYNDROME."
EX-99.1 to Form 6-K
Jun 4, 2026, 8:00 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS COMPLETED ACQUISITION OF CLINIQUANTUM."
EX-99.1 to Form 6-K
May 29, 2026, 7:40 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS RECEIVED CONDITIONAL REGULATORY APPROVAL FOR ACQUISITION OF CLINIQUANTUM."
EX-99.1 to Form 6-K
Mar 16, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS- CLEARMIND MEDICINE COLLABORATION LEADS TO PATENT APPLICATION FOR DEPRESSION THERAPY."
EX-99.1 to Form 6-K
Mar 12, 2026, 4:41 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS (75%) SIGNS DEFINITIVE AGREEMENT TO ACQUIRE MAJORITY STAKE IN CLINIQUANTUM, INNOVATOR IN QUANTUM-BASED CLINICAL TRAILS."
EX-99.1 to Form 6-K
Mar 12, 2026, 4:41 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS ANNOUNCES PUBLICATION OF INTERNATIONAL PATENT IN COLLABORATION WITH CLEARMIND MEDICINE FOR NOVEL THERAPY TARGETING WEIGHT LOSS AND FATTY LIVER DISEASE."
EX-99.2 to Form 6-K
Mar 2, 2026, 8:08 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD., DATED MARCH 2, 2026, TITLED "SCISPARC ANNOUNCES 1-FOR-9 REVERSE SHARE SPLIT"
EX-99.1 to Form 6-K
Feb 2, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS GRANTED U.S. PATENT FOR CANNABINOID TECHNOLOGY TO OVERCOME ANTIMICROBIAL RESISTANCE SUCH AS MRSA."
EX-99.1 to Form 6-K
Jan 26, 2026, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC SUCCESSFULLY COMPLETES ACQUISITION OF IP PORTFOLIO, ADVANCES TOWARD IMMEDIATE COMMERCIALIZATION."
EX-99.1 to Form 6-K
Jan 13, 2026, 7:10 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE A TREASURY OF PATENTS FOR THE ENDOSCOPE MARKET- ENTERING MULTI-BILLION DOLLAR OPPORTUNITY."
EX-99.1 to Form 6-K
Jan 12, 2026, 4:09 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION OF MINIMUM STOCKHOLDERS' EQUITY NON-COMPLIANCE."
EX-99.1 to Form 6-K
Dec 31, 2025, 8:16 AM ET
NOTICE AND PROXY STATEMENT FOR THE SPECIAL GENERAL MEETING TO BE HELD ON FEBRUARY 4, 2026
EX-99.1 to Form 6-K
Dec 31, 2025, 8:16 AM ET
PROXY CARD FOR THE SPECIAL GENERAL MEETING TO BE HELD ON FEBRUARY 4, 2026
EX-99.2 to Form 6-K
Dec 2, 2025, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS SIGNS NON-BINDING TERM SHEET TO ACQUIRE MAJORITY STAKE IN A QUANTUM ALGORITHM BIO DATA ANALYSIS COMPANY."
EX-99.1 to Form 6-K
Nov 26, 2025, 4:01 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC TO ACQUIRE TREASURY OF PATENTS FOR INNOVATIVE MEDICAL ENDOSCOPY SYSTEMS."
EX-99.1 to Form 6-K
Nov 20, 2025, 8:30 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS ANNOUNCES ISRAELI PATENT APPLICATION IN COLLABORATION WITH CLEARMIND MEDICINE FOR NOVEL NON-HALLUCINOGENIC NEUROPLASTOGEN TREATMENT FOR DEPRESSION."
EX-99.1 to Form 6-K
Nov 18, 2025, 4:00 PM ET
AS OF JUNE 30, 2025
EX-99.1 to Form 6-K
Nov 18, 2025, 4:00 PM ET
SCISPARC LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2025
EX-99.2 to Form 6-K
Oct 27, 2025, 7:52 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES CLOSING OF THE ACQUISITION OF A PUBLICLY TRADED COMPANY ON THE TSXV TO WHICH IT TRANSFERRED ITS ADVANCED CLINICAL STAGE PHARMACEUTICAL PORTFOLIO."
EX-99.1 to Form 6-K
Oct 24, 2025, 4:00 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES CLOSING OF THE SALE TO N2OFF OF MAJORITY-OWNED SUBSIDIARY MITOCAREX, ADVANCING DRUG DISCOVERY FOR RESISTANT CANCERS INCLUDING PANCREATIC AND NON-SMALL CELL LUNG CANCER."
EX-99.1 to Form 6-K
Oct 20, 2025, 9:25 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC-CLEARMIND COLLABORATION LEADS TO PUBLICATION OF U.S. PATENT APPLICATION TARGETING BINGE BEHAVIOR DISORDERS."
EX-99.1 to Form 6-K
Oct 15, 2025, 5:22 PM ET
ASSET AND SHARE PURCHASE AGREEMENT, DATED AS OF OCTOBER 9, 2025, BY AND BETWEEN SCISPARC LTD. AND MIZA III VENTURES INC
EX-99.1 to Form 6-K
Oct 15, 2025, 5:22 PM ET
PRESS RELEASE ISSUED BY SCISPARC LTD., DATED OCTOBER 15, 2025, TITLED "SCISPARC ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF A PUBLICLY TRADED COMPANY ON THE TSXV TO WHICH IT WILL TRANSFER ITS ADVANCED CLINICAL STAGE PHARMACEUTICAL PORTFOLIO"
EX-99.2 to Form 6-K
Oct 6, 2025, 7:35 AM ET
FRAMEWORK AGREEMENT, DATED AS OF OCTOBER 6, 2025, BY AND AMONG SCISPARC LTD., SCISPARC MERGER SUB LTD., AND AUTOMAX LTD
EX-99.1 to Form 6-K
Oct 6, 2025, 7:35 AM ET
PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC LTD. ANNOUNCES FRAMEWORK AGREEMENT REGARDING MERGER WITH AUTOMAX MOTORS."
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in SciSparc's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-9 reverse split on Apr 29, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRC.

Revenue growth-34.5% · median -15.4%

Operating margin-978.3% · median -3686.7%

Net margin-1422.8% · median -2117.2%

Company	Revenue	Growth
OVID	$1.58M	-76.2%
IGC	$1.12M	-15.4%
RFL	$980.00K	+33.9%
SPRC	$856.00K	-34.5%
XTLB	–	–
SPRB	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 3
Auditor: Brightman Almagor Zohar & Co.
SEC CIK: 1611746

Advertisement
300 × 250